{"gene":"RAP2B","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1990,"finding":"RAP2B was identified as a novel GTP-binding protein in human platelets, cloning from a platelet cDNA library. Bacterially expressed RAP2B binds both GTP and GDP in a Mg2+-dependent fashion with higher relative affinity for GTP than GDP, and is a ~22 kDa protein. Unlike the closely homologous RAP1A and RAP1B, RAP2B is not phosphorylated by the catalytic subunit of cAMP-dependent protein kinase.","method":"cDNA library screening, bacterial expression, GTP-binding assay on blots, in vitro kinase assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original biochemical characterization with in vitro GTP-binding assay and mutagenesis-level controls, replicated in companion paper","pmids":["2118648","2118346"],"is_preprint":false},{"year":1992,"finding":"A GTPase-activating protein (GAP) for RAP2B was partially purified from bovine brain membranes. This RAP2B-GAP (~55 kDa) stimulates GTP hydrolysis by RAP2B and is immunologically distinct from RAP1-GAP and RAS-GAP.","method":"Partial protein purification, GTPase activity assay, immunoblotting with specific antibodies","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro GAP activity assay with biochemical purification, but single study","pmids":["1472043"],"is_preprint":false},{"year":1993,"finding":"RAP2B associates with the platelet cytoskeleton upon platelet activation by thrombin, thromboxane analogue U46619, or thapsigargin. This translocation is dependent on platelet aggregation and requires fibrinogen binding to glycoprotein IIb-IIIa, as blocking fibrinogen binding completely prevents cytoskeletal incorporation of RAP2B.","method":"Triton X-100 fractionation, differential centrifugation, Western blot with specific antiserum, pharmacological inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — direct fractionation experiments with multiple agonists and pharmacological controls, replicated across multiple papers","pmids":["8356055"],"is_preprint":false},{"year":1993,"finding":"Microinjection of RAP2B protein or RNA into Xenopus oocytes causes rearrangement of pigment granules (mottling). This effect requires post-translational processing dependent on the C-terminal CAAX motif cysteine residue, as mutation of the CAAX cysteine to serine prevents membrane association and mottling. RAP2B associates with oocyte membranes in a CAAX-dependent manner.","method":"Microinjection into Xenopus oocytes, CAAX cysteine mutagenesis, membrane fractionation, in vitro transcription","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — functional mutagenesis with in vivo reconstitution in oocyte system establishing CAAX-dependent membrane association","pmids":["7684898"],"is_preprint":false},{"year":1994,"finding":"RAP2B translocation to the platelet cytoskeleton requires agonist-induced actin polymerization and depends on glycoprotein IIb-IIIa. Monoclonal antibodies against glycoprotein IIb-IIIa block RAP2B cytoskeletal translocation, and platelets from Glanzmann's thrombasthenia patients (lacking glycoprotein IIb-IIIa) fail to incorporate RAP2B into the cytoskeleton. RAP2B and glycoprotein IIb-IIIa co-translocate simultaneously to the cytoskeleton in comparable amounts.","method":"Triton X-100 fractionation, monoclonal antibody blocking, patient platelets (Glanzmann's thrombasthenia), comparative immunoblotting","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal antibody-blocking and genetic patient model providing orthogonal evidence for mechanism","pmids":["8183895"],"is_preprint":false},{"year":1999,"finding":"Von Willebrand factor (vWF) stimulation induces rapid translocation of RAP2B (and later RAP1B) to the platelet cytoskeleton via glycoprotein Ib engagement, requiring stirring (shear) but not integrin activation. This translocation is mediated by FcγII receptor-dependent protein tyrosine phosphorylation; blocking FcγII receptor or inhibiting tyrosine kinases (genistein) or elevating cAMP prevents RAP2B cytoskeletal association.","method":"Triton X-100 fractionation, monoclonal antibody blocking, kinase inhibition, cAMP-elevating agents, Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal pharmacological and antibody interventions establishing FcγII receptor-tyrosine kinase pathway","pmids":["10224142"],"is_preprint":false},{"year":2002,"finding":"RAP2B mediates stimulation of phospholipase C-epsilon (PLC-ε) downstream of Gs-coupled receptors and cyclic AMP signaling. The M3 muscarinic acetylcholine receptor activates RAP2B (GTP loading), and this RAP2B activation is required for PLC-ε stimulation. Dominant-negative RAP2B (but not inactive RAC1, RAS, RalA, RAP1A, or RAP2A) suppresses M3 mAChR-mediated PLC stimulation. The effect is mediated through EPAC1 (a cAMP-regulated GEF for Rap GTPases) and Gαs.","method":"Dominant-negative expression, adenylyl cyclase inhibitor (dd-Ado), GTP-loading assay, overexpression of PLC isoforms and catalytically inactive mutants, clostridial toxin inactivation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple dominant-negative/catalytic mutants with pharmacological controls establishing RAP2B-specific role in PLC-ε pathway","pmids":["11877431"],"is_preprint":false},{"year":2004,"finding":"EGF receptor activates RAP2B via a pathway involving PLC-γ1-dependent Ca2+/diacylglycerol activation of the GEF RasGRP3, which is then tyrosine-phosphorylated by c-Src. Activated RAP2B (GTP-loaded) binds directly to PLC-ε and induces its translocation to the plasma membrane, stimulating PLC/Ca2+ signaling. Dominant-negative RAP2B blocks EGF-induced PLC-ε activation.","method":"Dominant-negative expression, GTP-loading assay, co-immunoprecipitation (Rap2B-PLC-ε binding), plasma membrane translocation assay, c-Src inhibition, PLC-γ1 lipase-inactive mutant, intracellular Ca2+ chelation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — direct binding of RAP2B to PLC-ε shown by co-IP, translocation assay, and dominant-negative epistasis with multiple controls","pmids":["15143162"],"is_preprint":false},{"year":2004,"finding":"RAP2B is activated (GTP-loaded) in human platelets by thrombin, convulxin (GPVI ligand), and ADP (predominantly via P2Y12 receptor). Thrombin-induced RAP2B activation is partially dependent on secreted ADP, requires PI3K activity and intracellular Ca2+, but does not require thromboxane A2, cytoskeletal interaction, or integrin αIIbβ3 outside-in signaling. Convulxin-induced RAP2B activation additionally requires PKC.","method":"GTP-loading assay (pull-down with RAL-GDS-RBD), pharmacological inhibitors, ADP scavenging, specific receptor antagonists","journal":"Journal of thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 — multiple agonists and inhibitors used systematically to dissect upstream regulation of RAP2B activation","pmids":["15613030"],"is_preprint":false},{"year":2008,"finding":"RAP2B (but not RAP1B) localizes to lipid rafts in human platelets and transfected HEK293T cells. About 20% of RAP2B constitutively associates with lipid rafts. Palmitoylation at Cys176 and Cys177 (in addition to CAAX-dependent prenylation) is required for lipid raft targeting; mutation of either Cys176 or Cys177 to serine prevents raft association without altering general membrane localization. Disruption of lipid raft association by cholesterol depletion significantly impairs agonist-induced RAP2B activation and platelet aggregation.","method":"Lipid raft fractionation, metabolic [3H]palmitate labeling, site-directed mutagenesis of Cys176/Cys177, cholesterol depletion, platelet aggregation assay, transfection in HEK293T cells","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 1 — palmitoylation confirmed by metabolic labeling and mutagenesis; functional consequence of raft localization shown by cholesterol depletion","pmids":["18582561"],"is_preprint":false},{"year":2013,"finding":"RAP2B is a direct transcriptional target of p53. Upon DNA damage, p53 binds to the RAP2B promoter and activates its transcription. RAP2B promotes cell survival after DNA damage (pro-survival function), and siRNA-mediated knockdown of RAP2B sensitizes cells to DNA damage-induced apoptosis in a p53-dependent manner.","method":"Integrative genomic approach, chromatin immunoprecipitation (p53 binding to RAP2B promoter), siRNA knockdown, apoptosis assays, p53-dependent epistasis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrating direct p53 promoter binding, siRNA with p53-dependent epistasis providing mechanistic link","pmids":["23535297"],"is_preprint":false},{"year":2015,"finding":"RAP2B promotes breast cancer cell proliferation, migration, and invasion via a calcium-related ERK1/2 signaling pathway. RAP2B elevates intracellular calcium levels, which in turn promotes ERK1/2 phosphorylation. Calcium chelation (BAPTA/AM) or MEK inhibition (U0126) reverses RAP2B-induced ERK1/2 phosphorylation and the associated proliferative/migratory effects.","method":"siRNA knockdown, overexpression, CCK-8 assay, flow cytometry, transwell assay, Western blot, pharmacological inhibitors (BAPTA/AM, U0126)","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays with pharmacological epistasis, but pathway placement relies on inhibitor data only","pmids":["26201295"],"is_preprint":false},{"year":2015,"finding":"RAP2B regulates the cytoskeleton and inhibits cell spreading. Overexpression of RAP2B (but not the C180A mutant) inhibits cell spreading by disrupting actin dynamics upon nocodazole treatment. RAP2B expression is induced by nocodazole in a p53-dependent manner, though RAP2B itself is not required for p53-dependent cell cycle arrest.","method":"Western blot, immunofluorescence staining, overexpression and CAAX-motif mutagenesis (C180A), siRNA knockdown, nocodazole treatment","journal":"Journal of cancer research and clinical oncology","confidence":"Medium","confidence_rationale":"Tier 2 — functional mutagenesis (C180A) with actin staining showing mechanistic link between RAP2B membrane targeting and cytoskeletal effect","pmids":["25762091"],"is_preprint":false},{"year":2017,"finding":"RAP2B promotes cell migration and invasion in prostate cancer through activation of focal adhesion kinase (FAK). Elevated RAP2B increases phosphorylation of FAK, and a FAK-specific inhibitor (PF-573228) abolishes RAP2B-induced FAK phosphorylation and migration/invasion effects.","method":"siRNA knockdown, overexpression, CCK-8, transwell assay, Western blot for p-FAK, pharmacological FAK inhibition, in vivo xenograft","journal":"Medical oncology","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological epistasis with FAK inhibitor, but no direct RAP2B-FAK interaction shown","pmids":["27154636"],"is_preprint":false},{"year":2017,"finding":"RAP2B upregulates p53-mediated PLCε-IP3-Ca2+ signaling and inhibits autophagy. p53 increases intracellular IP3 and Ca2+ levels through its target gene Rap2B, and RAP2B decreases LC3 protein levels (autophagic flux marker), suggesting RAP2B suppresses starvation-triggered autophagy via the Rap2B-PLCε-IP3-Ca2+ pathway.","method":"Microarray identification of p53 targets, overexpression, siRNA knockdown, IP3/Ca2+ measurement, LC3 Western blot","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — functional measurements of IP3/Ca2+/LC3 in response to RAP2B manipulation, consistent with prior PLCε mechanism","pmids":["29029384"],"is_preprint":false},{"year":2017,"finding":"RAP2B promotes angiogenesis in renal cell carcinoma through the PI3K/AKT/VEGF signaling pathway. RAP2B knockdown decreases VEGF expression and secretion; RAP2B-mediated VEGF upregulation and endothelial tube formation are suppressed by PI3K inhibition.","method":"Western blot, qPCR, ELISA for VEGF, HUVEC growth and tube formation assay, siRNA knockdown, PI3K inhibitor, in vivo xenograft","journal":"Tumour biology","confidence":"Medium","confidence_rationale":"Tier 2 — functional tube formation assay with pharmacological PI3K inhibition, establishing pathway","pmids":["28691643"],"is_preprint":false},{"year":2019,"finding":"RAP2B promotes glioma cell adhesion, proliferation, migration, and invasion by regulating NF-κB signaling and expression of MMP-2 and MMP-9. Knockdown of RAP2B significantly reduces NF-κB, MMP-2, and MMP-9 protein levels in glioma cells.","method":"siRNA knockdown, CCK-8, cell attachment, transwell, wound-healing assay, Western blot for NF-κB/MMP-2/MMP-9","journal":"Journal of neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 3 — knockdown with Western blot pathway markers, but no direct RAP2B-NF-κB interaction shown","pmids":["30997639"],"is_preprint":false},{"year":2019,"finding":"RAP2B is recruited to the Coxiella replicative vacuole (CRV) in infected cells. Overexpression of active RAP2B (wild-type) but not its inactive ΔAAX mutant inhibits CRV development and blocks both homotypic (early phagosome fusion with CRV) and heterotypic (endosome/lysosome fusion with CRV) fusion events. RAP2B overexpression decreases v-SNARE VAMP7 levels, suggesting impaired membrane fusion capacity.","method":"Overexpression of RAP2B wt vs. ΔAAX mutant, fluorescence microscopy of CRV, VAMP7 Western blot","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — mutant vs. wild-type comparison with multiple fusion assays establishing GTPase-dependent mechanism","pmids":["30763357"],"is_preprint":false},{"year":2024,"finding":"RAP2B undergoes S-palmitoylation at C176/C177 that is required for its plasma membrane localization and promotion of cell migration and invasion in colorectal cancer, independent of proliferation. ABHD17a is identified as the depalmitoylating enzyme for RAP2B; ABHD17a activity alters RAP2B plasma membrane localization and inhibits cell migration. EGFR/PI3K signaling regulates RAP2B palmitoylation status by phosphorylating ABHD17a. A peptide blocking C176/C177 attenuates RAP2B palmitoylation, disrupts plasma membrane localization, and suppresses CRC metastasis in vivo.","method":"Palmitoylation assay, C176/C177 mutagenesis, ABHD17a knockdown/overexpression, subcellular fractionation, PI3K inhibition, ABHD17a phosphorylation assay, blocking peptide, in vivo metastasis model","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 — direct identification of depalmitoylating enzyme, palmitoylation site mutagenesis, and functional consequences in vivo with multiple orthogonal methods","pmids":["39277583"],"is_preprint":false},{"year":2025,"finding":"RAP2B interacts with plectin and enhances plectin expression, which in turn inhibits plectin-mediated F-actin assembly and drives intestinal cytoskeletal remodeling to promote colorectal cancer tumorigenesis. Intestine-specific knockout of Rap2B suppresses CRC initiation and progression in vivo, reducing metastatic potential.","method":"Intestine-specific knockout mouse model, co-immunoprecipitation (RAP2B-plectin interaction), F-actin assembly assays, tumor initiation/progression in vivo, Western blot","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP for RAP2B-plectin interaction combined with in vivo intestine-specific knockout phenotype","pmids":["40223002"],"is_preprint":false},{"year":2009,"finding":"RAP2B activates the NF-κB pathway when overexpressed in Rat1 cells, promoting transformation (focus formation). Reporter gene assay showed RAP2B activates NF-κB more than 3-fold over mock vector.","method":"Focus formation assay, NF-κB reporter gene assay, stable transfection","journal":"Chinese journal of lung cancer","confidence":"Low","confidence_rationale":"Tier 3 — reporter assay and focus formation without direct mechanistic linkage","pmids":["20719111"],"is_preprint":false},{"year":2024,"finding":"RAP2B was identified as a putative interactor of the luteinizing hormone receptor (LHR) by APEX2 proximity proteomics, with RAP2B modulating both LHR signaling and post-endocytic trafficking.","method":"APEX2 proximity proteomics, quantitative multiplexed proteomics with temporal profiling","journal":"bioRxiv (preprint)","confidence":"Low","confidence_rationale":"Tier 3 — proximity proteomics identification without direct functional validation of RAP2B-LHR interaction","pmids":["bio_10.1101_2024.06.14.599010"],"is_preprint":true}],"current_model":"RAP2B is a Ras-family small GTPase that cycles between GDP-bound (inactive) and GTP-bound (active) states; it is palmitoylated at Cys176/Cys177 (with ABHD17a as its depalmitoylase) for plasma membrane and lipid raft targeting, is transcriptionally induced by p53 to promote cell survival after DNA damage, and signals through direct binding to PLC-ε (stimulating IP3/Ca2+ production), through Ca2+-ERK1/2, PI3K/AKT, FAK, and NF-κB pathways to promote proliferation, migration, invasion, and angiogenesis, while also interacting with plectin to remodel the cytoskeleton and promoting platelet cytoskeletal reorganization downstream of glycoprotein IIb-IIIa and FcγII receptor-dependent tyrosine phosphorylation."},"narrative":{"teleology":[{"year":1990,"claim":"Identification of RAP2B as a novel Ras-family GTPase in platelets established that a distinct small GTPase—not a substrate of cAMP-dependent kinase—operates in platelet signaling.","evidence":"cDNA library screening from human platelets, bacterial expression, GTP/GDP-binding assays","pmids":["2118648","2118346"],"confidence":"High","gaps":["No effector or upstream regulator identified","Subcellular localization in platelets unknown","Biological function in platelets undetermined"]},{"year":1992,"claim":"Partial purification of a dedicated RAP2B-GAP from brain membranes demonstrated that RAP2B GTPase cycling is regulated by a specific, immunologically distinct GAP, not shared with RAP1 or RAS.","evidence":"Biochemical purification from bovine brain membranes, GTPase activity assay, immunoblotting","pmids":["1472043"],"confidence":"Medium","gaps":["GAP identity not molecularly cloned","In vivo relevance not established","No confirmation in human tissue"]},{"year":1993,"claim":"Demonstrating that RAP2B translocates to the platelet cytoskeleton upon activation and that this requires glycoprotein IIb-IIIa–mediated fibrinogen binding linked RAP2B to integrin outside-in signaling and cytoskeletal reorganization, while CAAX-dependent membrane association was shown to be necessary for RAP2B function in Xenopus oocytes.","evidence":"Triton X-100 fractionation of activated platelets with antibody blocking; Xenopus oocyte microinjection with CAAX cysteine mutagenesis","pmids":["8356055","7684898"],"confidence":"High","gaps":["Direct molecular link between RAP2B and cytoskeletal components unknown","GTP-loading status during translocation not measured","Signal upstream of integrin engagement not defined"]},{"year":1994,"claim":"Using Glanzmann's thrombasthenia patient platelets lacking glycoprotein IIb-IIIa provided genetic proof that integrin αIIbβ3 is required for RAP2B cytoskeletal translocation, solidifying the integrin dependency.","evidence":"Patient platelet fractionation, monoclonal antibody blocking","pmids":["8183895"],"confidence":"High","gaps":["Whether RAP2B is active (GTP-loaded) during translocation unknown","Direct physical interaction between RAP2B and integrin not demonstrated"]},{"year":1999,"claim":"Identification of a second pathway—FcγII receptor–dependent tyrosine phosphorylation downstream of GP Ib/vWF engagement—showed that RAP2B cytoskeletal recruitment is not exclusively integrin-dependent and involves tyrosine kinase signaling.","evidence":"FcγII receptor and tyrosine kinase inhibitor blocking, cAMP elevation, Western blot fractionation","pmids":["10224142"],"confidence":"High","gaps":["Identity of tyrosine kinase(s) phosphorylating downstream targets unknown","Whether RAP2B is a direct substrate of tyrosine phosphorylation untested"]},{"year":2002,"claim":"Discovery that RAP2B specifically mediates PLC-ε activation downstream of Gs-coupled receptors via EPAC1 identified the first effector pathway for RAP2B, distinguishing it functionally from RAP1A, RAP2A, and other small GTPases.","evidence":"Dominant-negative RAP2B, GTP-loading assays, adenylyl cyclase inhibitor, clostridial toxin inactivation in COS cells","pmids":["11877431"],"confidence":"High","gaps":["Direct physical interaction between RAP2B and PLC-ε not yet shown","Physiological context beyond COS cells not established"]},{"year":2004,"claim":"Demonstration of direct RAP2B–PLC-ε binding and plasma membrane recruitment downstream of EGFR via RasGRP3/c-Src established the molecular mechanism by which RAP2B activates PLC-ε, and systematic dissection of RAP2B activation in platelets by thrombin, ADP, and convulxin defined the upstream signaling requirements (PI3K, Ca²⁺, PKC).","evidence":"Co-immunoprecipitation of RAP2B and PLC-ε, translocation assay, dominant-negative epistasis; RAL-GDS-RBD pull-down GTP-loading assay with pharmacological inhibitors in platelets","pmids":["15143162","15613030"],"confidence":"High","gaps":["Structural basis of RAP2B–PLC-ε interaction unknown","Whether RAP2B–PLC-ε axis operates in platelets not shown"]},{"year":2008,"claim":"Identification of dual palmitoylation at Cys176/Cys177 as the determinant of lipid raft targeting—distinct from CAAX-dependent general membrane association—revealed a post-translational code that restricts RAP2B to specific membrane microdomains critical for agonist-induced activation.","evidence":"Metabolic [³H]palmitate labeling, C176S/C177S mutagenesis, lipid raft fractionation, cholesterol depletion in platelets and HEK293T","pmids":["18582561"],"confidence":"High","gaps":["Identity of the palmitoyl transferase unknown","Whether raft localization is dynamically regulated during signaling not addressed"]},{"year":2013,"claim":"ChIP evidence that p53 directly binds the RAP2B promoter to induce its transcription after DNA damage, and that RAP2B knockdown sensitizes cells to apoptosis, established RAP2B as a p53-regulated pro-survival factor linking the DNA damage response to small GTPase signaling.","evidence":"Chromatin immunoprecipitation, siRNA knockdown, apoptosis assays with p53-dependent epistasis","pmids":["23535297"],"confidence":"High","gaps":["Which RAP2B effector pathway mediates the survival signal unknown","Whether RAP2B induction is relevant in non-cancer p53-wild-type contexts not tested"]},{"year":2015,"claim":"Connecting RAP2B to Ca²⁺-dependent ERK1/2 activation in breast cancer and to CAAX-dependent inhibition of cell spreading via actin dynamics provided functional links between RAP2B's GTPase activity and downstream proliferation, migration, and cytoskeletal effects.","evidence":"Overexpression/knockdown with Ca²⁺ chelation and MEK inhibition; C180A mutagenesis with nocodazole-induced actin staining","pmids":["26201295","25762091"],"confidence":"Medium","gaps":["Whether ERK1/2 activation is PLC-ε–dependent or independent not resolved","Direct cytoskeletal binding partner of RAP2B not identified at this point"]},{"year":2017,"claim":"Extension of RAP2B signaling to PI3K/AKT/VEGF-mediated angiogenesis and to p53-driven PLC-ε-IP3-Ca²⁺ suppression of autophagy broadened the effector landscape of RAP2B beyond PLC-ε and ERK.","evidence":"PI3K inhibitor with VEGF ELISA and HUVEC tube formation; IP3/Ca²⁺ measurements and LC3 blotting after RAP2B manipulation","pmids":["28691643","29029384"],"confidence":"Medium","gaps":["Direct interaction between RAP2B and PI3K not demonstrated","Autophagy suppression assessed only by LC3 levels without autophagic flux assay"]},{"year":2019,"claim":"RAP2B was shown to be recruited to Coxiella replicative vacuoles where it inhibits membrane fusion in a CAAX-dependent manner, implicating it in host–pathogen membrane dynamics beyond classical signaling roles.","evidence":"Overexpression of wild-type vs. ΔAAX mutant, CRV fluorescence microscopy, VAMP7 Western blot","pmids":["30763357"],"confidence":"Medium","gaps":["Whether RAP2B recruitment is a host defense or pathogen exploitation strategy unknown","Mechanism linking RAP2B to VAMP7 reduction not established"]},{"year":2024,"claim":"Identification of ABHD17a as the RAP2B depalmitoylase regulated by EGFR/PI3K-dependent phosphorylation completed the palmitoylation cycle and showed that dynamic palmitoylation controls RAP2B membrane localization and metastatic potential in colorectal cancer in vivo.","evidence":"ABHD17a knockdown/overexpression, C176/C177 mutagenesis, palmitoylation assay, blocking peptide, in vivo metastasis model","pmids":["39277583"],"confidence":"High","gaps":["Palmitoyl acyltransferase(s) adding palmitate to RAP2B still unidentified","Whether ABHD17a regulation of RAP2B occurs in platelets not tested"]},{"year":2025,"claim":"Identification of plectin as a direct RAP2B interactor whose F-actin assembly activity is modulated by RAP2B, together with intestine-specific Rap2B knockout suppressing CRC, provided the first direct cytoskeletal binding partner for RAP2B and genetic loss-of-function evidence for its role in tumorigenesis.","evidence":"Co-immunoprecipitation of RAP2B–plectin, intestine-specific knockout mouse, F-actin assembly assays, in vivo tumor model","pmids":["40223002"],"confidence":"High","gaps":["Whether RAP2B–plectin interaction is GTP-dependent not addressed","Structural basis of RAP2B–plectin binding unknown","Whether plectin mediates RAP2B's platelet cytoskeletal effects untested"]},{"year":null,"claim":"Key open questions include the identity of the palmitoyl acyltransferase(s) for RAP2B, the structural basis of its interactions with PLC-ε and plectin, whether the PLC-ε–IP3–Ca²⁺ axis operates in platelets, and whether RAP2B directly engages PI3K or NF-κB components.","evidence":"","pmids":[],"confidence":"High","gaps":["Palmitoyl acyltransferase identity unknown","No structural model for RAP2B–effector complexes","PI3K and NF-κB pathway connections lack evidence of direct interaction"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[0,1,6,7,8]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[2,4,19]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,7,9,18]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[2,4,5,12,19]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,9]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[2,4,5,8,9]}],"complexes":[],"partners":["PLCE1","PLEC","ABHD17A","RASGRP3","RAPGEF3"],"other_free_text":[]},"mechanistic_narrative":"RAP2B is a Ras-family small GTPase that functions as a signaling switch in platelet activation, phospholipase C-ε regulation, cytoskeletal remodeling, and cell survival after DNA damage. In platelets, RAP2B is activated by thrombin, ADP (via P2Y12), and convulxin through PI3K- and Ca²⁺-dependent pathways, and translocates to the cytoskeleton in a glycoprotein IIb-IIIa– and FcγII receptor–dependent manner [PMID:8356055, PMID:8183895, PMID:10224142, PMID:15613030]. GTP-loaded RAP2B directly binds and recruits PLC-ε to the plasma membrane downstream of both Gs-coupled receptors (via EPAC1) and EGF receptor (via RasGRP3/c-Src), stimulating IP3 production and intracellular Ca²⁺ release that feed into ERK1/2 signaling [PMID:11877431, PMID:15143162, PMID:26201295]. Dual palmitoylation at Cys176/Cys177—reversed by the depalmitoylase ABHD17a under EGFR/PI3K control—directs RAP2B to lipid rafts and the plasma membrane, and is essential for its roles in platelet activation, cytoskeletal regulation via plectin interaction, and promotion of migration and metastasis in colorectal cancer [PMID:18582561, PMID:39277583, PMID:40223002]. RAP2B is also a direct p53 transcriptional target that promotes cell survival after DNA damage [PMID:23535297]."},"prefetch_data":{"uniprot":{"accession":"P61225","full_name":"Ras-related protein Rap-2b","aliases":[],"length_aa":183,"mass_kda":20.5,"function":"Small GTP-binding protein which cycles between a GDP-bound inactive and a GTP-bound active form. Involved in EGFR and CHRM3 signaling pathways through stimulation of PLCE1. May play a role in cytoskeletal rearrangements and regulate cell spreading through activation of the effector TNIK. May regulate membrane vesiculation in red blood cells","subcellular_location":"Recycling endosome membrane","url":"https://www.uniprot.org/uniprotkb/P61225/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RAP2B","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RAP2B","total_profiled":1310},"omim":[{"mim_id":"611418","title":"SMALL G PROTEIN SIGNALING MODULATOR 2; SGSM2","url":"https://www.omim.org/entry/611418"},{"mim_id":"611417","title":"SMALL G PROTEIN SIGNALING MODULATOR 1; SGSM1","url":"https://www.omim.org/entry/611417"},{"mim_id":"610440","title":"SMALL G PROTEIN SIGNALING MODULATOR 3; SGSM3","url":"https://www.omim.org/entry/610440"},{"mim_id":"609530","title":"RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; RAPGEF2","url":"https://www.omim.org/entry/609530"},{"mim_id":"608414","title":"PHOSPHOLIPASE C, EPSILON-1; PLCE1","url":"https://www.omim.org/entry/608414"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RAP2B"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P61225","domains":[{"cath_id":"3.40.50.300","chopping":"1-167","consensus_level":"high","plddt":95.6579,"start":1,"end":167}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P61225","model_url":"https://alphafold.ebi.ac.uk/files/AF-P61225-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P61225-F1-predicted_aligned_error_v6.png","plddt_mean":90.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RAP2B","jax_strain_url":"https://www.jax.org/strain/search?query=RAP2B"},"sequence":{"accession":"P61225","fasta_url":"https://rest.uniprot.org/uniprotkb/P61225.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P61225/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P61225"}},"corpus_meta":[{"pmid":"26201295","id":"PMC_26201295","title":"Rap2B promotes proliferation, migration, and invasion of human breast cancer through calcium-related ERK1/2 signaling pathway.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26201295","citation_count":73,"is_preprint":false},{"pmid":"2118648","id":"PMC_2118648","title":"RAP2B: a RAS-related GTP-binding protein from platelets.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2118648","citation_count":72,"is_preprint":false},{"pmid":"25663460","id":"PMC_25663460","title":"miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25663460","citation_count":67,"is_preprint":false},{"pmid":"11877431","id":"PMC_11877431","title":"Stimulation of phospholipase C-epsilon by the M3 muscarinic acetylcholine receptor mediated by cyclic AMP and the GTPase Rap2B.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11877431","citation_count":62,"is_preprint":false},{"pmid":"34239562","id":"PMC_34239562","title":"Exosomes miR-22-3p Derived from Mesenchymal Stem Cells Suppress Colorectal Cancer Cell Proliferation and Invasion by Regulating RAP2B and PI3K/AKT Pathway.","date":"2021","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34239562","citation_count":55,"is_preprint":false},{"pmid":"28409547","id":"PMC_28409547","title":"Long Noncoding RNA XIST Promotes Osteosarcoma Progression by Targeting Ras-Related Protein RAP2B via miR-320b.","date":"2017","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/28409547","citation_count":53,"is_preprint":false},{"pmid":"23535297","id":"PMC_23535297","title":"Rap2b, a novel p53 target, regulates p53-mediated pro-survival function.","date":"2013","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23535297","citation_count":48,"is_preprint":false},{"pmid":"10224142","id":"PMC_10224142","title":"Rap1B and Rap2B translocation to the cytoskeleton by von Willebrand factor involves FcgammaII receptor-mediated protein tyrosine phosphorylation.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10224142","citation_count":46,"is_preprint":false},{"pmid":"27133066","id":"PMC_27133066","title":"MiR-194 inhibits cell proliferation and invasion via repression of RAP2B in bladder cancer.","date":"2016","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/27133066","citation_count":44,"is_preprint":false},{"pmid":"15143162","id":"PMC_15143162","title":"Rap2B-dependent stimulation of phospholipase C-epsilon by epidermal growth factor receptor mediated by c-Src phosphorylation of RasGRP3.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15143162","citation_count":44,"is_preprint":false},{"pmid":"8356055","id":"PMC_8356055","title":"Association of the low molecular weight GTP-binding protein rap2B with the cytoskeleton during platelet aggregation.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8356055","citation_count":43,"is_preprint":false},{"pmid":"28691643","id":"PMC_28691643","title":"Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28691643","citation_count":28,"is_preprint":false},{"pmid":"8183895","id":"PMC_8183895","title":"Glycoprotein IIb-IIIa and the translocation of Rap2B to the platelet cytoskeleton.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8183895","citation_count":28,"is_preprint":false},{"pmid":"18582561","id":"PMC_18582561","title":"Targeting of the small GTPase Rap2b, but not Rap1b, to lipid rafts is promoted by palmitoylation at Cys176 and Cys177 and is required for efficient protein activation in human platelets.","date":"2008","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18582561","citation_count":21,"is_preprint":false},{"pmid":"31121595","id":"PMC_31121595","title":"MicroRNA-147b Promotes Proliferation and Invasion of Human Colorectal Cancer by Targeting RAS Oncogene Family (RAP2B).","date":"2019","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31121595","citation_count":20,"is_preprint":false},{"pmid":"27154636","id":"PMC_27154636","title":"Rap2B promotes cell proliferation, migration and invasion in prostate cancer.","date":"2016","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27154636","citation_count":18,"is_preprint":false},{"pmid":"24951956","id":"PMC_24951956","title":"Rap2B promotes migration and invasion of human suprarenal epithelioma.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24951956","citation_count":17,"is_preprint":false},{"pmid":"35260078","id":"PMC_35260078","title":"TMEM43 promotes pancreatic cancer progression by stabilizing PRPF3 and regulating RAP2B/ERK axis.","date":"2022","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/35260078","citation_count":17,"is_preprint":false},{"pmid":"28081729","id":"PMC_28081729","title":"Knockdown of Rap2B Inhibits the Proliferation and Invasion in Hepatocellular Carcinoma Cells.","date":"2017","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/28081729","citation_count":16,"is_preprint":false},{"pmid":"2118346","id":"PMC_2118346","title":"Properties of the exchange rate of guanine nucleotides to the novel rap-2B protein.","date":"1990","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2118346","citation_count":15,"is_preprint":false},{"pmid":"27073477","id":"PMC_27073477","title":"Structure, functional regulation and signaling properties of Rap2B.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27073477","citation_count":14,"is_preprint":false},{"pmid":"15613030","id":"PMC_15613030","title":"Activation of the small GTPase Rap2B in agonist-stimulated human platelets.","date":"2004","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/15613030","citation_count":14,"is_preprint":false},{"pmid":"26671640","id":"PMC_26671640","title":"Rap2b promotes proliferation, migration, and invasion of lung cancer cells.","date":"2015","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/26671640","citation_count":14,"is_preprint":false},{"pmid":"27012552","id":"PMC_27012552","title":"Rap2B GTPase: structure, functions, and regulation.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27012552","citation_count":12,"is_preprint":false},{"pmid":"30997639","id":"PMC_30997639","title":"Rap2B promotes cell adhesion, proliferation, migration and invasion of human glioma.","date":"2019","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30997639","citation_count":12,"is_preprint":false},{"pmid":"28390112","id":"PMC_28390112","title":"Knockdown of Rap2B, a Ras Superfamily Protein, Inhibits Proliferation, Migration, and Invasion in Cervical Cancer Cells via Regulating the ERK1/2 Signaling Pathway.","date":"2017","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/28390112","citation_count":12,"is_preprint":false},{"pmid":"39277583","id":"PMC_39277583","title":"Inhibiting S-palmitoylation arrests metastasis by relocating Rap2b from plasma membrane in colorectal cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39277583","citation_count":11,"is_preprint":false},{"pmid":"32052247","id":"PMC_32052247","title":"Rap2B knockdown suppresses malignant progression of hepatocellular carcinoma by inactivating the PTEN/PI3K/Akt and ERK1/2 pathways.","date":"2020","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32052247","citation_count":11,"is_preprint":false},{"pmid":"25762091","id":"PMC_25762091","title":"p53 target gene Rap2B regulates the cytoskeleton and inhibits cell spreading.","date":"2015","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25762091","citation_count":11,"is_preprint":false},{"pmid":"28423503","id":"PMC_28423503","title":"Rap2b siRNA significantly enhances the anticancer therapeutic efficacy of adriamycin in a gold nanoshell-based drug/gene co-delivery system.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28423503","citation_count":10,"is_preprint":false},{"pmid":"20719111","id":"PMC_20719111","title":"[Identification and Functional Analysis of A Novel Candidate Oncogene RAP2B in Lung Cancer.].","date":"2009","source":"Zhongguo fei ai za zhi = Chinese journal of lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20719111","citation_count":10,"is_preprint":false},{"pmid":"33692846","id":"PMC_33692846","title":"Rap2B promotes the proliferation and migration of human glioma cells via activation of the ERK pathway.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33692846","citation_count":9,"is_preprint":false},{"pmid":"30763357","id":"PMC_30763357","title":"The cAMP effectors, Rap2b and EPAC, are involved in the regulation of the development of the Coxiella burnetii containing vacuole by altering the fusogenic capacity of the vacuole.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30763357","citation_count":7,"is_preprint":false},{"pmid":"33023331","id":"PMC_33023331","title":"Long non-coding RNA CCAT1 promotes non-small cell lung cancer progression by regulating the miR-216a-5p/RAP2B axis.","date":"2020","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/33023331","citation_count":7,"is_preprint":false},{"pmid":"33123297","id":"PMC_33123297","title":"Long non-coding RNA GHET1/miR-105/RAP2B axis regulates the progression of acute myeloid leukemia.","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33123297","citation_count":7,"is_preprint":false},{"pmid":"33123239","id":"PMC_33123239","title":"Long non-coding RNA SNHG6 promotes tumorigenesis in melanoma cells via the microRNA-101-3p/RAP2B axis.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33123239","citation_count":6,"is_preprint":false},{"pmid":"29029384","id":"PMC_29029384","title":"p53 upregulates PLCε-IP3-Ca2+ pathway and inhibits autophagy through its target gene Rap2B.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29029384","citation_count":6,"is_preprint":false},{"pmid":"7684898","id":"PMC_7684898","title":"Microinjection of Rap2B protein or RNA induces rearrangement of pigment granules in Xenopus oocytes.","date":"1993","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7684898","citation_count":6,"is_preprint":false},{"pmid":"32596241","id":"PMC_32596241","title":"miR-205 Expression Elevated With EDS Treatment and Induced Leydig Cell Apoptosis by Targeting RAP2B via the PI3K/AKT Signaling Pathway.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32596241","citation_count":6,"is_preprint":false},{"pmid":"36499729","id":"PMC_36499729","title":"MiR-199a-3p Induces Mesenchymal to Epithelial Transition of Keratinocytes by Targeting RAP2B.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36499729","citation_count":4,"is_preprint":false},{"pmid":"20726223","id":"PMC_20726223","title":"[Effects of Rap2b gene on foci formation and wound-healing of NIH3T3 cells].","date":"2010","source":"Wei sheng yan jiu = Journal of hygiene research","url":"https://pubmed.ncbi.nlm.nih.gov/20726223","citation_count":4,"is_preprint":false},{"pmid":"26308105","id":"PMC_26308105","title":"Expression and DNA methylation status of the Rap2B gene in human bronchial epithelial cells treated by cigarette smoke condensate.","date":"2015","source":"Inhalation toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26308105","citation_count":2,"is_preprint":false},{"pmid":"40223002","id":"PMC_40223002","title":"Rap2B drives tumorigenesis and progression of colorectal cancer through intestinal cytoskeleton remodeling.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40223002","citation_count":1,"is_preprint":false},{"pmid":"36958293","id":"PMC_36958293","title":"Hsa_circ_0008035 Knockdown Inhibits Bladder Cancer Progression through miR-1184/RAP2B Axis.","date":"2023","source":"Urologia internationalis","url":"https://pubmed.ncbi.nlm.nih.gov/36958293","citation_count":1,"is_preprint":false},{"pmid":"1472043","id":"PMC_1472043","title":"Partial purification of a GTPase-activating protein for rap2b from bovine brain membranes.","date":"1992","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1472043","citation_count":1,"is_preprint":false},{"pmid":"36444911","id":"PMC_36444911","title":"MicroRNA-708 suppresses the proliferation, migration, and invasion of human retinoblastoma cells by targeting RAP2B, a member of the RAS oncogene family.","date":"2022","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/36444911","citation_count":0,"is_preprint":false},{"pmid":"38385110","id":"PMC_38385110","title":"[Retracted] Long non‑coding RNA SNHG6 promotes tumorigenesis in melanoma cells via the microRNA‑101‑3p/RAP2B axis.","date":"2024","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/38385110","citation_count":0,"is_preprint":false},{"pmid":"41094393","id":"PMC_41094393","title":"Rap2B-mediated reprogramming of the PI3K/AKT signaling axis drives resistance to cetuximab-targeted therapy in colorectal carcinoma.","date":"2025","source":"Biological procedures online","url":"https://pubmed.ncbi.nlm.nih.gov/41094393","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.06.14.599010","title":"A spatiotemporally resolved GPCR interactome reveals novel mediators of receptor agonism","date":"2024-06-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.14.599010","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":23823,"output_tokens":5903,"usd":0.080007},"stage2":{"model":"claude-opus-4-6","input_tokens":9529,"output_tokens":3721,"usd":0.211005},"total_usd":0.291012,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"RAP2B was identified as a novel GTP-binding protein in human platelets, cloning from a platelet cDNA library. Bacterially expressed RAP2B binds both GTP and GDP in a Mg2+-dependent fashion with higher relative affinity for GTP than GDP, and is a ~22 kDa protein. Unlike the closely homologous RAP1A and RAP1B, RAP2B is not phosphorylated by the catalytic subunit of cAMP-dependent protein kinase.\",\n      \"method\": \"cDNA library screening, bacterial expression, GTP-binding assay on blots, in vitro kinase assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original biochemical characterization with in vitro GTP-binding assay and mutagenesis-level controls, replicated in companion paper\",\n      \"pmids\": [\"2118648\", \"2118346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"A GTPase-activating protein (GAP) for RAP2B was partially purified from bovine brain membranes. This RAP2B-GAP (~55 kDa) stimulates GTP hydrolysis by RAP2B and is immunologically distinct from RAP1-GAP and RAS-GAP.\",\n      \"method\": \"Partial protein purification, GTPase activity assay, immunoblotting with specific antibodies\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro GAP activity assay with biochemical purification, but single study\",\n      \"pmids\": [\"1472043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"RAP2B associates with the platelet cytoskeleton upon platelet activation by thrombin, thromboxane analogue U46619, or thapsigargin. This translocation is dependent on platelet aggregation and requires fibrinogen binding to glycoprotein IIb-IIIa, as blocking fibrinogen binding completely prevents cytoskeletal incorporation of RAP2B.\",\n      \"method\": \"Triton X-100 fractionation, differential centrifugation, Western blot with specific antiserum, pharmacological inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct fractionation experiments with multiple agonists and pharmacological controls, replicated across multiple papers\",\n      \"pmids\": [\"8356055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Microinjection of RAP2B protein or RNA into Xenopus oocytes causes rearrangement of pigment granules (mottling). This effect requires post-translational processing dependent on the C-terminal CAAX motif cysteine residue, as mutation of the CAAX cysteine to serine prevents membrane association and mottling. RAP2B associates with oocyte membranes in a CAAX-dependent manner.\",\n      \"method\": \"Microinjection into Xenopus oocytes, CAAX cysteine mutagenesis, membrane fractionation, in vitro transcription\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional mutagenesis with in vivo reconstitution in oocyte system establishing CAAX-dependent membrane association\",\n      \"pmids\": [\"7684898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"RAP2B translocation to the platelet cytoskeleton requires agonist-induced actin polymerization and depends on glycoprotein IIb-IIIa. Monoclonal antibodies against glycoprotein IIb-IIIa block RAP2B cytoskeletal translocation, and platelets from Glanzmann's thrombasthenia patients (lacking glycoprotein IIb-IIIa) fail to incorporate RAP2B into the cytoskeleton. RAP2B and glycoprotein IIb-IIIa co-translocate simultaneously to the cytoskeleton in comparable amounts.\",\n      \"method\": \"Triton X-100 fractionation, monoclonal antibody blocking, patient platelets (Glanzmann's thrombasthenia), comparative immunoblotting\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal antibody-blocking and genetic patient model providing orthogonal evidence for mechanism\",\n      \"pmids\": [\"8183895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Von Willebrand factor (vWF) stimulation induces rapid translocation of RAP2B (and later RAP1B) to the platelet cytoskeleton via glycoprotein Ib engagement, requiring stirring (shear) but not integrin activation. This translocation is mediated by FcγII receptor-dependent protein tyrosine phosphorylation; blocking FcγII receptor or inhibiting tyrosine kinases (genistein) or elevating cAMP prevents RAP2B cytoskeletal association.\",\n      \"method\": \"Triton X-100 fractionation, monoclonal antibody blocking, kinase inhibition, cAMP-elevating agents, Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal pharmacological and antibody interventions establishing FcγII receptor-tyrosine kinase pathway\",\n      \"pmids\": [\"10224142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RAP2B mediates stimulation of phospholipase C-epsilon (PLC-ε) downstream of Gs-coupled receptors and cyclic AMP signaling. The M3 muscarinic acetylcholine receptor activates RAP2B (GTP loading), and this RAP2B activation is required for PLC-ε stimulation. Dominant-negative RAP2B (but not inactive RAC1, RAS, RalA, RAP1A, or RAP2A) suppresses M3 mAChR-mediated PLC stimulation. The effect is mediated through EPAC1 (a cAMP-regulated GEF for Rap GTPases) and Gαs.\",\n      \"method\": \"Dominant-negative expression, adenylyl cyclase inhibitor (dd-Ado), GTP-loading assay, overexpression of PLC isoforms and catalytically inactive mutants, clostridial toxin inactivation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple dominant-negative/catalytic mutants with pharmacological controls establishing RAP2B-specific role in PLC-ε pathway\",\n      \"pmids\": [\"11877431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"EGF receptor activates RAP2B via a pathway involving PLC-γ1-dependent Ca2+/diacylglycerol activation of the GEF RasGRP3, which is then tyrosine-phosphorylated by c-Src. Activated RAP2B (GTP-loaded) binds directly to PLC-ε and induces its translocation to the plasma membrane, stimulating PLC/Ca2+ signaling. Dominant-negative RAP2B blocks EGF-induced PLC-ε activation.\",\n      \"method\": \"Dominant-negative expression, GTP-loading assay, co-immunoprecipitation (Rap2B-PLC-ε binding), plasma membrane translocation assay, c-Src inhibition, PLC-γ1 lipase-inactive mutant, intracellular Ca2+ chelation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding of RAP2B to PLC-ε shown by co-IP, translocation assay, and dominant-negative epistasis with multiple controls\",\n      \"pmids\": [\"15143162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RAP2B is activated (GTP-loaded) in human platelets by thrombin, convulxin (GPVI ligand), and ADP (predominantly via P2Y12 receptor). Thrombin-induced RAP2B activation is partially dependent on secreted ADP, requires PI3K activity and intracellular Ca2+, but does not require thromboxane A2, cytoskeletal interaction, or integrin αIIbβ3 outside-in signaling. Convulxin-induced RAP2B activation additionally requires PKC.\",\n      \"method\": \"GTP-loading assay (pull-down with RAL-GDS-RBD), pharmacological inhibitors, ADP scavenging, specific receptor antagonists\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple agonists and inhibitors used systematically to dissect upstream regulation of RAP2B activation\",\n      \"pmids\": [\"15613030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RAP2B (but not RAP1B) localizes to lipid rafts in human platelets and transfected HEK293T cells. About 20% of RAP2B constitutively associates with lipid rafts. Palmitoylation at Cys176 and Cys177 (in addition to CAAX-dependent prenylation) is required for lipid raft targeting; mutation of either Cys176 or Cys177 to serine prevents raft association without altering general membrane localization. Disruption of lipid raft association by cholesterol depletion significantly impairs agonist-induced RAP2B activation and platelet aggregation.\",\n      \"method\": \"Lipid raft fractionation, metabolic [3H]palmitate labeling, site-directed mutagenesis of Cys176/Cys177, cholesterol depletion, platelet aggregation assay, transfection in HEK293T cells\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — palmitoylation confirmed by metabolic labeling and mutagenesis; functional consequence of raft localization shown by cholesterol depletion\",\n      \"pmids\": [\"18582561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RAP2B is a direct transcriptional target of p53. Upon DNA damage, p53 binds to the RAP2B promoter and activates its transcription. RAP2B promotes cell survival after DNA damage (pro-survival function), and siRNA-mediated knockdown of RAP2B sensitizes cells to DNA damage-induced apoptosis in a p53-dependent manner.\",\n      \"method\": \"Integrative genomic approach, chromatin immunoprecipitation (p53 binding to RAP2B promoter), siRNA knockdown, apoptosis assays, p53-dependent epistasis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct p53 promoter binding, siRNA with p53-dependent epistasis providing mechanistic link\",\n      \"pmids\": [\"23535297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RAP2B promotes breast cancer cell proliferation, migration, and invasion via a calcium-related ERK1/2 signaling pathway. RAP2B elevates intracellular calcium levels, which in turn promotes ERK1/2 phosphorylation. Calcium chelation (BAPTA/AM) or MEK inhibition (U0126) reverses RAP2B-induced ERK1/2 phosphorylation and the associated proliferative/migratory effects.\",\n      \"method\": \"siRNA knockdown, overexpression, CCK-8 assay, flow cytometry, transwell assay, Western blot, pharmacological inhibitors (BAPTA/AM, U0126)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with pharmacological epistasis, but pathway placement relies on inhibitor data only\",\n      \"pmids\": [\"26201295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RAP2B regulates the cytoskeleton and inhibits cell spreading. Overexpression of RAP2B (but not the C180A mutant) inhibits cell spreading by disrupting actin dynamics upon nocodazole treatment. RAP2B expression is induced by nocodazole in a p53-dependent manner, though RAP2B itself is not required for p53-dependent cell cycle arrest.\",\n      \"method\": \"Western blot, immunofluorescence staining, overexpression and CAAX-motif mutagenesis (C180A), siRNA knockdown, nocodazole treatment\",\n      \"journal\": \"Journal of cancer research and clinical oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional mutagenesis (C180A) with actin staining showing mechanistic link between RAP2B membrane targeting and cytoskeletal effect\",\n      \"pmids\": [\"25762091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RAP2B promotes cell migration and invasion in prostate cancer through activation of focal adhesion kinase (FAK). Elevated RAP2B increases phosphorylation of FAK, and a FAK-specific inhibitor (PF-573228) abolishes RAP2B-induced FAK phosphorylation and migration/invasion effects.\",\n      \"method\": \"siRNA knockdown, overexpression, CCK-8, transwell assay, Western blot for p-FAK, pharmacological FAK inhibition, in vivo xenograft\",\n      \"journal\": \"Medical oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological epistasis with FAK inhibitor, but no direct RAP2B-FAK interaction shown\",\n      \"pmids\": [\"27154636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RAP2B upregulates p53-mediated PLCε-IP3-Ca2+ signaling and inhibits autophagy. p53 increases intracellular IP3 and Ca2+ levels through its target gene Rap2B, and RAP2B decreases LC3 protein levels (autophagic flux marker), suggesting RAP2B suppresses starvation-triggered autophagy via the Rap2B-PLCε-IP3-Ca2+ pathway.\",\n      \"method\": \"Microarray identification of p53 targets, overexpression, siRNA knockdown, IP3/Ca2+ measurement, LC3 Western blot\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional measurements of IP3/Ca2+/LC3 in response to RAP2B manipulation, consistent with prior PLCε mechanism\",\n      \"pmids\": [\"29029384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RAP2B promotes angiogenesis in renal cell carcinoma through the PI3K/AKT/VEGF signaling pathway. RAP2B knockdown decreases VEGF expression and secretion; RAP2B-mediated VEGF upregulation and endothelial tube formation are suppressed by PI3K inhibition.\",\n      \"method\": \"Western blot, qPCR, ELISA for VEGF, HUVEC growth and tube formation assay, siRNA knockdown, PI3K inhibitor, in vivo xenograft\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional tube formation assay with pharmacological PI3K inhibition, establishing pathway\",\n      \"pmids\": [\"28691643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RAP2B promotes glioma cell adhesion, proliferation, migration, and invasion by regulating NF-κB signaling and expression of MMP-2 and MMP-9. Knockdown of RAP2B significantly reduces NF-κB, MMP-2, and MMP-9 protein levels in glioma cells.\",\n      \"method\": \"siRNA knockdown, CCK-8, cell attachment, transwell, wound-healing assay, Western blot for NF-κB/MMP-2/MMP-9\",\n      \"journal\": \"Journal of neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — knockdown with Western blot pathway markers, but no direct RAP2B-NF-κB interaction shown\",\n      \"pmids\": [\"30997639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RAP2B is recruited to the Coxiella replicative vacuole (CRV) in infected cells. Overexpression of active RAP2B (wild-type) but not its inactive ΔAAX mutant inhibits CRV development and blocks both homotypic (early phagosome fusion with CRV) and heterotypic (endosome/lysosome fusion with CRV) fusion events. RAP2B overexpression decreases v-SNARE VAMP7 levels, suggesting impaired membrane fusion capacity.\",\n      \"method\": \"Overexpression of RAP2B wt vs. ΔAAX mutant, fluorescence microscopy of CRV, VAMP7 Western blot\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutant vs. wild-type comparison with multiple fusion assays establishing GTPase-dependent mechanism\",\n      \"pmids\": [\"30763357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RAP2B undergoes S-palmitoylation at C176/C177 that is required for its plasma membrane localization and promotion of cell migration and invasion in colorectal cancer, independent of proliferation. ABHD17a is identified as the depalmitoylating enzyme for RAP2B; ABHD17a activity alters RAP2B plasma membrane localization and inhibits cell migration. EGFR/PI3K signaling regulates RAP2B palmitoylation status by phosphorylating ABHD17a. A peptide blocking C176/C177 attenuates RAP2B palmitoylation, disrupts plasma membrane localization, and suppresses CRC metastasis in vivo.\",\n      \"method\": \"Palmitoylation assay, C176/C177 mutagenesis, ABHD17a knockdown/overexpression, subcellular fractionation, PI3K inhibition, ABHD17a phosphorylation assay, blocking peptide, in vivo metastasis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct identification of depalmitoylating enzyme, palmitoylation site mutagenesis, and functional consequences in vivo with multiple orthogonal methods\",\n      \"pmids\": [\"39277583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RAP2B interacts with plectin and enhances plectin expression, which in turn inhibits plectin-mediated F-actin assembly and drives intestinal cytoskeletal remodeling to promote colorectal cancer tumorigenesis. Intestine-specific knockout of Rap2B suppresses CRC initiation and progression in vivo, reducing metastatic potential.\",\n      \"method\": \"Intestine-specific knockout mouse model, co-immunoprecipitation (RAP2B-plectin interaction), F-actin assembly assays, tumor initiation/progression in vivo, Western blot\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP for RAP2B-plectin interaction combined with in vivo intestine-specific knockout phenotype\",\n      \"pmids\": [\"40223002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RAP2B activates the NF-κB pathway when overexpressed in Rat1 cells, promoting transformation (focus formation). Reporter gene assay showed RAP2B activates NF-κB more than 3-fold over mock vector.\",\n      \"method\": \"Focus formation assay, NF-κB reporter gene assay, stable transfection\",\n      \"journal\": \"Chinese journal of lung cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — reporter assay and focus formation without direct mechanistic linkage\",\n      \"pmids\": [\"20719111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RAP2B was identified as a putative interactor of the luteinizing hormone receptor (LHR) by APEX2 proximity proteomics, with RAP2B modulating both LHR signaling and post-endocytic trafficking.\",\n      \"method\": \"APEX2 proximity proteomics, quantitative multiplexed proteomics with temporal profiling\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — proximity proteomics identification without direct functional validation of RAP2B-LHR interaction\",\n      \"pmids\": [\"bio_10.1101_2024.06.14.599010\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"RAP2B is a Ras-family small GTPase that cycles between GDP-bound (inactive) and GTP-bound (active) states; it is palmitoylated at Cys176/Cys177 (with ABHD17a as its depalmitoylase) for plasma membrane and lipid raft targeting, is transcriptionally induced by p53 to promote cell survival after DNA damage, and signals through direct binding to PLC-ε (stimulating IP3/Ca2+ production), through Ca2+-ERK1/2, PI3K/AKT, FAK, and NF-κB pathways to promote proliferation, migration, invasion, and angiogenesis, while also interacting with plectin to remodel the cytoskeleton and promoting platelet cytoskeletal reorganization downstream of glycoprotein IIb-IIIa and FcγII receptor-dependent tyrosine phosphorylation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"RAP2B is a Ras-family small GTPase that functions as a signaling switch in platelet activation, phospholipase C-ε regulation, cytoskeletal remodeling, and cell survival after DNA damage. In platelets, RAP2B is activated by thrombin, ADP (via P2Y12), and convulxin through PI3K- and Ca²⁺-dependent pathways, and translocates to the cytoskeleton in a glycoprotein IIb-IIIa– and FcγII receptor–dependent manner [PMID:8356055, PMID:8183895, PMID:10224142, PMID:15613030]. GTP-loaded RAP2B directly binds and recruits PLC-ε to the plasma membrane downstream of both Gs-coupled receptors (via EPAC1) and EGF receptor (via RasGRP3/c-Src), stimulating IP3 production and intracellular Ca²⁺ release that feed into ERK1/2 signaling [PMID:11877431, PMID:15143162, PMID:26201295]. Dual palmitoylation at Cys176/Cys177—reversed by the depalmitoylase ABHD17a under EGFR/PI3K control—directs RAP2B to lipid rafts and the plasma membrane, and is essential for its roles in platelet activation, cytoskeletal regulation via plectin interaction, and promotion of migration and metastasis in colorectal cancer [PMID:18582561, PMID:39277583, PMID:40223002]. RAP2B is also a direct p53 transcriptional target that promotes cell survival after DNA damage [PMID:23535297].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Identification of RAP2B as a novel Ras-family GTPase in platelets established that a distinct small GTPase—not a substrate of cAMP-dependent kinase—operates in platelet signaling.\",\n      \"evidence\": \"cDNA library screening from human platelets, bacterial expression, GTP/GDP-binding assays\",\n      \"pmids\": [\"2118648\", \"2118346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No effector or upstream regulator identified\", \"Subcellular localization in platelets unknown\", \"Biological function in platelets undetermined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Partial purification of a dedicated RAP2B-GAP from brain membranes demonstrated that RAP2B GTPase cycling is regulated by a specific, immunologically distinct GAP, not shared with RAP1 or RAS.\",\n      \"evidence\": \"Biochemical purification from bovine brain membranes, GTPase activity assay, immunoblotting\",\n      \"pmids\": [\"1472043\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GAP identity not molecularly cloned\", \"In vivo relevance not established\", \"No confirmation in human tissue\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrating that RAP2B translocates to the platelet cytoskeleton upon activation and that this requires glycoprotein IIb-IIIa–mediated fibrinogen binding linked RAP2B to integrin outside-in signaling and cytoskeletal reorganization, while CAAX-dependent membrane association was shown to be necessary for RAP2B function in Xenopus oocytes.\",\n      \"evidence\": \"Triton X-100 fractionation of activated platelets with antibody blocking; Xenopus oocyte microinjection with CAAX cysteine mutagenesis\",\n      \"pmids\": [\"8356055\", \"7684898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link between RAP2B and cytoskeletal components unknown\", \"GTP-loading status during translocation not measured\", \"Signal upstream of integrin engagement not defined\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Using Glanzmann's thrombasthenia patient platelets lacking glycoprotein IIb-IIIa provided genetic proof that integrin αIIbβ3 is required for RAP2B cytoskeletal translocation, solidifying the integrin dependency.\",\n      \"evidence\": \"Patient platelet fractionation, monoclonal antibody blocking\",\n      \"pmids\": [\"8183895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RAP2B is active (GTP-loaded) during translocation unknown\", \"Direct physical interaction between RAP2B and integrin not demonstrated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of a second pathway—FcγII receptor–dependent tyrosine phosphorylation downstream of GP Ib/vWF engagement—showed that RAP2B cytoskeletal recruitment is not exclusively integrin-dependent and involves tyrosine kinase signaling.\",\n      \"evidence\": \"FcγII receptor and tyrosine kinase inhibitor blocking, cAMP elevation, Western blot fractionation\",\n      \"pmids\": [\"10224142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of tyrosine kinase(s) phosphorylating downstream targets unknown\", \"Whether RAP2B is a direct substrate of tyrosine phosphorylation untested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery that RAP2B specifically mediates PLC-ε activation downstream of Gs-coupled receptors via EPAC1 identified the first effector pathway for RAP2B, distinguishing it functionally from RAP1A, RAP2A, and other small GTPases.\",\n      \"evidence\": \"Dominant-negative RAP2B, GTP-loading assays, adenylyl cyclase inhibitor, clostridial toxin inactivation in COS cells\",\n      \"pmids\": [\"11877431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between RAP2B and PLC-ε not yet shown\", \"Physiological context beyond COS cells not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstration of direct RAP2B–PLC-ε binding and plasma membrane recruitment downstream of EGFR via RasGRP3/c-Src established the molecular mechanism by which RAP2B activates PLC-ε, and systematic dissection of RAP2B activation in platelets by thrombin, ADP, and convulxin defined the upstream signaling requirements (PI3K, Ca²⁺, PKC).\",\n      \"evidence\": \"Co-immunoprecipitation of RAP2B and PLC-ε, translocation assay, dominant-negative epistasis; RAL-GDS-RBD pull-down GTP-loading assay with pharmacological inhibitors in platelets\",\n      \"pmids\": [\"15143162\", \"15613030\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of RAP2B–PLC-ε interaction unknown\", \"Whether RAP2B–PLC-ε axis operates in platelets not shown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of dual palmitoylation at Cys176/Cys177 as the determinant of lipid raft targeting—distinct from CAAX-dependent general membrane association—revealed a post-translational code that restricts RAP2B to specific membrane microdomains critical for agonist-induced activation.\",\n      \"evidence\": \"Metabolic [³H]palmitate labeling, C176S/C177S mutagenesis, lipid raft fractionation, cholesterol depletion in platelets and HEK293T\",\n      \"pmids\": [\"18582561\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the palmitoyl transferase unknown\", \"Whether raft localization is dynamically regulated during signaling not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"ChIP evidence that p53 directly binds the RAP2B promoter to induce its transcription after DNA damage, and that RAP2B knockdown sensitizes cells to apoptosis, established RAP2B as a p53-regulated pro-survival factor linking the DNA damage response to small GTPase signaling.\",\n      \"evidence\": \"Chromatin immunoprecipitation, siRNA knockdown, apoptosis assays with p53-dependent epistasis\",\n      \"pmids\": [\"23535297\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which RAP2B effector pathway mediates the survival signal unknown\", \"Whether RAP2B induction is relevant in non-cancer p53-wild-type contexts not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connecting RAP2B to Ca²⁺-dependent ERK1/2 activation in breast cancer and to CAAX-dependent inhibition of cell spreading via actin dynamics provided functional links between RAP2B's GTPase activity and downstream proliferation, migration, and cytoskeletal effects.\",\n      \"evidence\": \"Overexpression/knockdown with Ca²⁺ chelation and MEK inhibition; C180A mutagenesis with nocodazole-induced actin staining\",\n      \"pmids\": [\"26201295\", \"25762091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ERK1/2 activation is PLC-ε–dependent or independent not resolved\", \"Direct cytoskeletal binding partner of RAP2B not identified at this point\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extension of RAP2B signaling to PI3K/AKT/VEGF-mediated angiogenesis and to p53-driven PLC-ε-IP3-Ca²⁺ suppression of autophagy broadened the effector landscape of RAP2B beyond PLC-ε and ERK.\",\n      \"evidence\": \"PI3K inhibitor with VEGF ELISA and HUVEC tube formation; IP3/Ca²⁺ measurements and LC3 blotting after RAP2B manipulation\",\n      \"pmids\": [\"28691643\", \"29029384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct interaction between RAP2B and PI3K not demonstrated\", \"Autophagy suppression assessed only by LC3 levels without autophagic flux assay\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"RAP2B was shown to be recruited to Coxiella replicative vacuoles where it inhibits membrane fusion in a CAAX-dependent manner, implicating it in host–pathogen membrane dynamics beyond classical signaling roles.\",\n      \"evidence\": \"Overexpression of wild-type vs. ΔAAX mutant, CRV fluorescence microscopy, VAMP7 Western blot\",\n      \"pmids\": [\"30763357\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether RAP2B recruitment is a host defense or pathogen exploitation strategy unknown\", \"Mechanism linking RAP2B to VAMP7 reduction not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of ABHD17a as the RAP2B depalmitoylase regulated by EGFR/PI3K-dependent phosphorylation completed the palmitoylation cycle and showed that dynamic palmitoylation controls RAP2B membrane localization and metastatic potential in colorectal cancer in vivo.\",\n      \"evidence\": \"ABHD17a knockdown/overexpression, C176/C177 mutagenesis, palmitoylation assay, blocking peptide, in vivo metastasis model\",\n      \"pmids\": [\"39277583\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Palmitoyl acyltransferase(s) adding palmitate to RAP2B still unidentified\", \"Whether ABHD17a regulation of RAP2B occurs in platelets not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of plectin as a direct RAP2B interactor whose F-actin assembly activity is modulated by RAP2B, together with intestine-specific Rap2B knockout suppressing CRC, provided the first direct cytoskeletal binding partner for RAP2B and genetic loss-of-function evidence for its role in tumorigenesis.\",\n      \"evidence\": \"Co-immunoprecipitation of RAP2B–plectin, intestine-specific knockout mouse, F-actin assembly assays, in vivo tumor model\",\n      \"pmids\": [\"40223002\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RAP2B–plectin interaction is GTP-dependent not addressed\", \"Structural basis of RAP2B–plectin binding unknown\", \"Whether plectin mediates RAP2B's platelet cytoskeletal effects untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the identity of the palmitoyl acyltransferase(s) for RAP2B, the structural basis of its interactions with PLC-ε and plectin, whether the PLC-ε–IP3–Ca²⁺ axis operates in platelets, and whether RAP2B directly engages PI3K or NF-κB components.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Palmitoyl acyltransferase identity unknown\", \"No structural model for RAP2B–effector complexes\", \"PI3K and NF-κB pathway connections lack evidence of direct interaction\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [0, 1, 6, 7, 8]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [2, 4, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 7, 9, 18]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [2, 4, 5, 12, 19]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [6, 7, 8, 11, 15]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [2, 4, 5, 8, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PLCE1\",\n      \"PLEC\",\n      \"ABHD17a\",\n      \"RASGRP3\",\n      \"RAPGEF3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}